$1,318.00
This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, key upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Risk factors
8 Diagnosis
8 Patient segmentation
10 TREATMENT
10 Rate control strategy
10 Rhythm control strategy
11 Medications to prevent thromboembolism
12 Medical procedures or surgery
14 EPIDEMIOLOGY
18 MARKETED DRUGS
18 Atrial fibrillation/flutter
21 SPAF
23 PIPELINE DRUGS
23 Atrial fibrillation/flutter
27 SPAF
31 RECENT EVENTS AND ANALYST OPINION
31 AGN-151607 for Atrial Fibrillation/Flutter (November 7, 2022)
32 Asundexian for SPAF (August 29, 2022)
33 Asundexian for SPAF (April 3, 2022)
36 KEY UPCOMING EVENTS
37 KEY REGULATORY EVENTS
37 Galaxy Gets CE Mark For Centauri PEF Pulsed Field Ablation System
37 AliveCor’s Smartphone-Linked ECG First Product Assessed Under UK’s Rapid HTA Pilot
37 Minute Insight: Acutus Adds Another Device To The Left-Heart Business It Sold To Medtronic
38 Teva Introduces First Eliquis Rival In UK
38 Minute Insight: Abbott’s Aveir VR To Take On Medtronic’s Micra In US Leadless Pacemaker Market
38 Cardiovascular Catch-Up: AliveCor Launches Card-Size ECG
40 PROBABILITY OF SUCCESS
40 Atrial fibrillation/flutter
40 SPAF
42 LICENSING AND ASSET ACQUISITION DEALS
42 Medtronic Acquires Affera For $925m
42 Acutus Sells Left-Heart Access Business To Medtronic; Extends Its Cash Runway
42 Boston Scientific Builds Momentum In Electrophysiology
44 REVENUE OPPORTUNITY
46 CLINICAL TRIAL LANDSCAPE
47 Sponsors by status
48 Sponsors by phase
49 Recent events
53 BIBLIOGRAPHY
55 APPENDIX
LIST OF FIGURES
17 Figure 1: Trends in prevalent cases of atrial fibrillation, 2018–27
23 Figure 2: Overview of pipeline drugs for atrial fibrillation/flutter in the US
24 Figure 3: Pipeline drugs for atrial fibrillation/flutter, by company
24 Figure 4: Pipeline drugs for atrial fibrillation/flutter, by drug type
24 Figure 5: Pipeline drugs for atrial fibrillation/flutter, by classification
27 Figure 6: Overview of pipeline drugs for SPAF in the US
27 Figure 7: Pipeline drugs for SPAF, by company
28 Figure 8: Pipeline drugs for SPAF, by drug type
28 Figure 9: Pipeline drugs for SPAF, by classification
32 Figure 10: AGN-151607 for Atrial Fibrillation/Flutter (November 7, 2022): Phase II – NOVA
36 Figure 11: Key upcoming events in atrial fibrillation
40 Figure 12: Probability of success in the atrial fibrillation/flutter pipeline
41 Figure 13: Probability of success in the SPAF pipeline
46 Figure 14: Clinical trials in atrial fibrillation
46 Figure 15: Top 10 drugs for clinical trials in atrial fibrillation
47 Figure 16: Top 10 companies for clinical trials in atrial fibrillation
47 Figure 17: Trial locations in atrial fibrillation
48 Figure 18: Atrial fibrillation trials status
49 Figure 19: Atrial fibrillation trials sponsors, by phase
LIST OF TABLES
15 Table 1: Prevalent cases of atrial fibrillation, 2018–27
19 Table 2: Marketed drugs for atrial fibrillation/flutter
22 Table 3: Marketed drugs for SPAF
26 Table 4: Pipeline drugs for atrial fibrillation/flutter in the US
29 Table 5: Pipeline drugs for SPAF in the US
31 Table 6: AGN-151607 for Atrial Fibrillation/Flutter (November 7, 2022)
32 Table 7: Asundexian for SPAF (August 29, 2022)
34 Table 8: Asundexian for SPAF (April 3, 2022)
44 Table 9: Historical global sales, by drug ($m), 2017–21
45 Table 10: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!